Jiangsu Hengrui Pharmaceuticals (01276): SHR-1139 injection approved for clinical trials
Hengrui Medicine (01276) announced that its subsidiary, Guangdong Hengrui Pharmaceutical Co., Ltd., recently received a notification from the National Medical Products Administration...
Jiangsu Hengrui Pharmaceuticals (01276) announced that its subsidiary, Guangdong Jiangsu Hengrui Pharmaceuticals Co., Ltd., has recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for SHR-1139 injection, and will soon commence clinical trials.
SHR-1139 injection is a biopharmaceutical developed independently by the company, which is expected to synergistically enhance the treatment of ulcerative colitis by inhibiting inflammatory reactions and maintaining epithelial barriers. Currently, there are no similar drugs approved for marketing domestically or internationally. As of now, the accumulated research and development investment for SHR-1139 injection is approximately RMB 71.28 million.
Related Articles
Sanhui Integrated (603163.SH): Employee shareholding platform Suzhou Shengzhan plans to reduce its stake in the company by no more than 0.62%.
TIME WATCH (02033) issued a profit warning, anticipating an annual loss of HK$17 million for the company's shareholders compared to a profit.
DONGFENG GROUP(00489): Ho Well Financial is approved and appointed as independent financial advisor
Sanhui Integrated (603163.SH): Employee shareholding platform Suzhou Shengzhan plans to reduce its stake in the company by no more than 0.62%.
TIME WATCH (02033) issued a profit warning, anticipating an annual loss of HK$17 million for the company's shareholders compared to a profit.
DONGFENG GROUP(00489): Ho Well Financial is approved and appointed as independent financial advisor
